Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review
Open accessAbstract
The eyebrows frame the upper margin of the orbit and are an essential feature of the facial landscape. Eyebrow hypotrichosis, also known as madarosis, is characterized by a lack of growth or loss of eyebrow hair. Eyebrow loss can have cosmetic, functional, and social consequences. Eyebrow hypotrichosis can be idiopathic or related to an underlying condition. Bimatoprost 0.03% solution is a prostamide F2α analog indicated for the treatment of glaucoma and ocular hypertension that has also demonstrated efficacy for hair growth; indeed, it is currently approved by the Food and Drug Administration for the treatment of eyelash hypotrichosis. A 60-year-old woman with eyebrow hypotrichosis is described who achieved excellent and sustained growth of her eyebrows with continual daily application of bimatoprost 0.03% solution. We discuss the therapeutic mechanisms of bimatoprost 0.03% solution in hair growth, review other potential modalities for treating eyebrow hypotrichosis, and summarize the findings of investigators who have utilized bimatoprost in the treatment of eyebrow hypotrichosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
No standard evidence-based treatment exists for eyebrow hypotrichosis apart from topical medications, intralesional injections, surgical transplantation, camouflage, and microblading.
“No standard evidence-based treatment exists for eybrow hypotrichosis apart from topical medications, intralesional injections, surgical transplantation as well as camouflage and microblading [3].”
From Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial (2023) · cites this paper as [3]
The Discussion (page unavailable) lists topical bimatoprost and minoxidil and hair transplantation as options, while the Conclusions say treatment modalities are limited and further studies are needed. The paper does not state that no standard evidence-based treatment exists, and it does not mention intralesional injections, camouflage, or microblading. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lee, S., Tanglertsampan, C., Tanchotikul, M., & Worapunpong, N. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12275 · Cited by 19 · see citing works
Flagged first, then by citations
Research works printed but not linked: 13
- [1]Eyebrow loss: clinical review Am J Clin Dermatol Velez N Khera P English JC 3rd 337 346 8 2007 18039016
- [2]Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis Drug Des Devel Ther Chanasumon N Sriphojanart T Suchonwanit P 365 372 12 2018 PMC5826207 29503529
- [3]Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study Dermatol Surg Beer KR Julius H Dunn M Wilson F 1079 1087 39 2013 23617229
- [4]Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases Dermatol Online J Vergilis-Kalner IJ 4 20 2014 https://escholarship.org/uc/item/1mc5v5mx 24945645
- [5]Topical bimatoprost for the treatment of eyebrow hypotrichosis J Drugs Dermatol Schweiger ES Pinchover L Bernstein RM 106 108 11 2012 http://jddonline.com/articles/dermatology/S1545961612P0106X/1 22206085
- [6]Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study J Dermatol Suwanchatchai W Tanglertsampan C Pengsalae N Makornwattana M 865 866 39 2012 22594928
- [7]Bimatoprost ophthalmic solution 0.03% for eyebrow growth Dermatol Surg Elias MJ Weiss J Weiss E 1057 1059 37 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21457389 21457389
- [8]Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia Expert Opin Investig Drugs Barrón-Hernández YL Tosti A 515 522 26 2017 28264599
- [9]Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis Dermatol Surg Carruthers J Beer K Carruthers A 608 617 42 2106 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414776/ PMC5414776 27124878
- [11]Facial hair restoration: hair transplantation to eyebrows, beard, sideburns, and eyelashes Facial Plast Surg Clin North Am Epstein J 457 467 21 2013 24017987
- [12]Eyebrow regrowth in patient with atrophic scarring alopecia treated with an autologous fat graft Dermatol Surg Dini M Mori A Quattrini Li A 926 928 40 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25006850 25006850
- [13]Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth Dermatol Surg Cohen JL 1361 1371 36 2010 20384750
- [14]Bimatoprost-induced periocular skin hyperpigmentation: histopathological study Arch Ophthalmol Kapur R Osmanovic S Toyran S Edward DP 1541 1546 123 2005 16286616
Cited by
Sorted by citations
Zaky, M. S., Hashem, O. A., Mahfouz, S. M., & Elsaie, M. L. (2023) · Archives of Dermatological Research · doi:10.1007/s00403-023-02679-2 · Cited by 6 · see citing works
- Authors
- Riahi, R. R., & Cohen, P. R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Riahi, Ryan R
- Venue
- Cureus
- Published
- 2018-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e2666-e2666
- ISSN
- 2168-8184 (ISSN-L)
- PMC
- PMC6054329
- OpenAlex
- W2803954671
- Cited by
- 13
- References
- 1
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 1 · 2021: 1 · 2019: 5 · 2018: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Cureus (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Urology › Hair Growth and Disorders
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Keywords
- madarosis, bimatoprost
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
